Organ Rejection Prophylaxis Drugs Market

Market Overview

Organ rejection prophylaxis drugs are intended to prevent graft rejection, reduce morbidity, and complications prior to or during transplant surgery. Universal organ rejection prophylaxis drugs involve administration of an antimicrobial agent to contain risk for infection while pre-emptive organ rejection prophylaxis drugs are aimed at neutralizing antigens and antibodies so as to avoid graft rejection by immunosuppression.

Organ Rejection Prophylaxis Drugs Market: Drivers and Restraints

The rising organ replacement surgeries are the prime driver of the organ rejection prophylaxis drugs market. According to the National Kidney Foundation, 107 kidney transplants took place in the U.S. in 2014. According to Organ Donation Foundation of South Africa (ODF), 512 solid organs and corneas were transplanted in South Africa, in 2016 and 4 300 patients were in waiting lines for organs. 

The long waiting times owing to the high demand for organ transplant is expected to drive a sustainable market. According to estimates of the American Transplant Foundation, 115,000 patients in the U.S. are on the waiting list for an organ transplant.

The growing risk factors resulting in organ damage such as trauma, increase in geriatric patients and diseases such as diabetes, hypertension, and stroke is driving a large patient base for an organ transplant. The growing rates of organ donations owing to awareness is another driver of the market. According to the American Transplant Foundation, one-fourth donors are not biologically related to the recipient, resulting in greater risk of organ rejection.

However, the constraints such as high cost of organ transplant surgery, scarcity of organs, and the high cost of drugs coupled are hampering the organ rejection prophylaxis drugs market. Ethical issues such as possible negative externalities are also restricting the market.

Concerns regarding social and economic inequality owing to wealthy individuals benefiting and disadvantaging poor people is another barrier that has to be mitigated. The poor healthcare infrastructure and the paucity of trained surgeons is another barrier to the market.

Organ Rejection Prophylaxis Drugs Market: Segmentation

Based on drug class	Cytostatics Corticosteroids Antibodies Immunophilins Others
based on application	Chest Heart Lung Heart Abdomen Kidney Liver Pancreas Other Tissues, cells and fluids Cornea Skin Bone, bone marrow/Adult stem cell Others
Region	North America (U.S., Canada) Latin America (Mexico, Brazil) Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX) Eastern Europe (Russia, Poland, Rest Of Eastern Europe) Asia Pacific Excluding Japan (China, India, Australia & New Zealand) Japan Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Organ Rejection Prophylaxis Drugs Market: Overview

Based on regions, the global organ rejection prophylaxis drugs market is classified into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East & Africa, and Asia Pacific market excluding Japan. North America led by the U.S. is expected to account for the largest share of the global organ rejection prophylaxis drugs market owing to excellent healthcare infrastructure, large per capita income, developed economy, attractive reimbursement and faster adoption of new technology.

The Europe organ rejection prophylaxis drugs markets are expected to be led by the Germany, France, Italy, Spain, Portugal and the UK. Germany has a large pharmaceutical industry which is a prime driver of the European organ rejection prophylaxis drugs market.

The Latin America and the Middle East and Africa organ rejection prophylaxis drugs market is constrained due to the low healthcare expenditure and poor economic conditions. The Middle East and Africa organ rejection prophylaxis drugs market is projected to be dominated by the Gulf economies of UAE, Saudi Arabia, and Kuwait owing to their large wealth relative to the African nations.

The Asia Pacific market is expected to expand at a furious pace owing to growing research and development expenditure and the support of the governments to the technology sector. The growing economy of China and India is expected to drive large market adoption.

Some of the major players in the global organ rejection prophylaxis drugs market are Novartis AG, Astellas Pharma, Inc., CSC Pharmaceuticals, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi, and others.

The organ rejection prophylaxis drugs report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on organ rejection prophylaxis drugs market segments and geographies.

The global Organ Rejection Prophylaxis Drugs report covers exhaustive analysis

• Organ Rejection Prophylaxis Drugs Market Segments
• Organ Rejection Prophylaxis Drugs Market Dynamics
• Organ Rejection Prophylaxis Drugs Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Report Highlights

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.

To know more about delivery timeline for this report Contact Sales